Nordea Investment Management AB Increases Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Nordea Investment Management AB grew its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 4.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 125,400 shares of the company’s stock after buying an additional 5,300 shares during the period. Nordea Investment Management AB’s holdings in CRISPR Therapeutics were worth $4,913,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in CRSP. Bank of New York Mellon Corp grew its stake in shares of CRISPR Therapeutics by 4.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 78,692 shares of the company’s stock valued at $4,250,000 after buying an additional 3,378 shares during the period. Natixis Advisors LLC lifted its holdings in shares of CRISPR Therapeutics by 3.8% during the 2nd quarter. Natixis Advisors LLC now owns 10,906 shares of the company’s stock valued at $589,000 after acquiring an additional 400 shares in the last quarter. National Bank of Canada FI lifted its holdings in shares of CRISPR Therapeutics by 35.0% during the 2nd quarter. National Bank of Canada FI now owns 848 shares of the company’s stock valued at $46,000 after acquiring an additional 220 shares in the last quarter. Arizona State Retirement System lifted its holdings in shares of CRISPR Therapeutics by 8.9% during the 2nd quarter. Arizona State Retirement System now owns 22,579 shares of the company’s stock valued at $1,219,000 after acquiring an additional 1,841 shares in the last quarter. Finally, Wedbush Securities Inc. lifted its holdings in shares of CRISPR Therapeutics by 6.9% during the 2nd quarter. Wedbush Securities Inc. now owns 5,677 shares of the company’s stock valued at $307,000 after acquiring an additional 366 shares in the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 30,000 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $55.62, for a total value of $1,668,600.00. Following the completion of the transaction, the chief executive officer now owns 196,540 shares in the company, valued at approximately $10,931,554.80. This represents a 13.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, General Counsel James R. Kasinger sold 1,089 shares of the company’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the completion of the transaction, the general counsel now owns 62,597 shares of the company’s stock, valued at approximately $2,896,989.16. This trade represents a 1.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 50,382 shares of company stock valued at $2,744,179 in the last quarter. Insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Stock Performance

Shares of CRISPR Therapeutics stock opened at $39.69 on Friday. The firm has a market cap of $3.39 billion, a PE ratio of -14.02 and a beta of 1.68. The firm’s 50-day simple moving average is $46.39 and its 200-day simple moving average is $48.83. CRISPR Therapeutics AG has a 1 year low of $38.20 and a 1 year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The business had revenue of $0.60 million for the quarter, compared to analyst estimates of $6.65 million. During the same quarter in the prior year, the business posted ($1.41) EPS. On average, equities analysts predict that CRISPR Therapeutics AG will post -5.13 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on CRSP. Barclays reduced their target price on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 6th. Chardan Capital restated a “buy” rating and set a $94.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, December 10th. JMP Securities restated a “market outperform” rating and set a $86.00 target price on shares of CRISPR Therapeutics in a report on Friday, December 20th. Bank of America cut their price objective on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $78.38.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.